Loading
Ajanta Pharma Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by J K TRIPATHI, was filed 19 Dec 2023.
Insider Decl.
241
Thresholds
n/a
Buy Volume
€11,820
17 ops. · all time
Sell Volume
€96M
46 ops. · all time
Who traded when
BuySaleJ K Tripathi5 sales
Shailesh R Singh5 sales
Ravi Agrawal, Trustee Ravi Agrawal Trust1 sale
Ravi P Agrawal, Trustee Ravi Agrawal Trust1 sale
Vandana Shailesh Singh1 sale
Since the insiders bought
- +23.9%Entry ₹2,174.25 · Close at T+365 ₹2,694.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Ajanta Pharma Limited Buy (bullish), based on 13 analysts. Average price target: ₹3,808.38.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 7,832 of 26,280 companies
61.7
score / 100
Value34
Quality89
FCF yld0.4%
Earn yld2.6%
EV/EBITDA26.4x
ROE25%
Gross mgn77%
Net mgn20%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹3,264.10
Analyst consensus
13 analystsBuy
₹3,109.00Target ₹3,808.38(+17%)₹4,155.00
Income statement
Revenue₹54.1B
Gross profit₹41.6B77% margin
EBITDA₹15.7B29% margin
Net income₹10.6B19.6% margin
Valuation
PER (trailing)36.0x
PER (forward)28.0x
P/Book9.0x
Beta0.22
Balance sheet & cash
Market cap₹407.9B
Total debt₹2.6B
Free Cash Flow₹1.6B
Debt / Equity6%
Profitability & ownership
ROE25.4%
ROA14.8%
% insiders54.3%
% institutions24.3%
Last declaration on 22 October 2026
Declarations241 total
30,000 shares-CreationSEBI:b52632acca7de425a27d8304437f00aa20d31ad2
460,000 shares-CreationSEBI:c06d81a076bda1c8f4fccc76572129bde15c187c
18,518 shares-ReleaseSEBI:6b564b07ee7a69a976452b33bd14fccbcc61679d
460,000 sharesEquity SharesAcquisition of Shares - Encumbrance creationSEBI:ec4533d8a4a24c9332a106d0927305573ea02aea
925,926 shares-ReleaseSEBI:8763c8d333c48fd5457e96f53e73d568458ac33c
976,000 shares-ReleaseSEBI:2314bfdbffa5666d2d7d19f062030e3510fa18cf
6,910 shares-ReleaseSEBI:740c354a087512198cda289d794f5b4a7715cbe7
23,800 shares-ReleaseSEBI:c3d7f41b1f584ac1269dc1207899c260fc8db28f
925,926 shares-ReleaseSEBI:65e4d0989259a9d451011e32356df9f4597f5ea3
2,600 shares-ReleaseSEBI:247a8cf3b6d83fe541d75e2c4b9f64e29b2a3a37
976,726 shares-CreationSEBI:ead8630f74472610584fcc8e1cb7d93b309eabd8
177,648 shares-ReleaseSEBI:6a05ed8db31c5e91887e3914aaf23ffda7baa8f3
160,000 shares-ReleaseSEBI:2709fb289834b803e3b178ea8710c5f6e11c4a42
907,904 shares-ReleaseSEBI:0f7a8d2688a9992b28f0e7026888bd577edf5d3f
892,860 shares-CreationSEBI:1f800c3bbc2e580845c0835419f82045823be5f1
3,450,000 shares-MarketSEBI:d03f4fb4f674f13cb0a3eed34d50b6215512b182
3,450,000 shares@ ₹2,968.002.28% mcap100.0% of flowEquity SharesMarket SaleSEBI:33e708f621deff484b43c7871b5950db0a1e8899
2,770,000 shares@ ₹2,915.80100.0% of flowEquity SharesCreation Of PledgeSEBI:f7a15d49a29fa9453a0137fae4fb5845fd665220
2,855,925 shares@ ₹2,915.80100.0% of flowEquity SharesCreation Of PledgeSEBI:99a556c77e14d6a776ff59dc60463fa522242449
192,500 shares-ReleaseSEBI:391d90f34dbd0336ab618fa9b7db4f97ce598151
100,000 shares-ReleaseSEBI:e3afdda03195464dfc20c81e1c50ced0827000ef
607 shares@ ₹3,100.17960.0005% mcap6.7% of flowEquity SharesSEBI:09f83c50e1bac8e6003c99c5247da57a14155d52
750 shares@ ₹2,713.087.3% of flowEquity SharesSEBI:1dcb887468b5d4a74fb919411c27e99e7893a57e
2,000 shares@ ₹2,565.4118.9% of flowEquity SharesSEBI:b8a8da2a9bbe096359fd6d548efbdff8ec27f242
3,000 shares@ ₹2,528.4327.9% of flowEquity SharesSEBI:7a5683ef306d063ae8f127f6c5f38c223198f465
25 of 241 declarations
About Ajanta Pharma Limited
On June 9, 2026, Ravi P Agrawal, trustee of the Ravi Agrawal Trust (Promoter), filed a sale of EUR 93,016,529 at Ajanta Pharma Limited, nearly the whole amount of the 46 sales in the record (EUR 95.9 million in total, median EUR 19,288). On December 22, 2022, two other trustee sales follow: EUR 1,124,933 for Ravi P Agrawal and EUR 330,775 for Aayush M Agrawal.
Purchases are of a different order: 17 purchases for EUR 11,820 in all (median EUR 536), so purchases are 27% of trades. The three largest are by J K Tripathi, EUR 2,552 on November 7, 2023, EUR 1,451 on November 3, 2023 and EUR 1,044 on December 12, 2023. J K Tripathi files 26 filings, 17 of them purchases and 8 sales.
Read moreShow less
The record holds 240 filings from 49 filers, 175 of them of another kind. The two Agrawal trusts are among the most active (30 and 29 filings for Ravi, 26 and 23 for Aayush). This Indian healthcare and pharma company has a market capitalisation of INR 407.9 billion, and insiders hold 54.3% of it. Annual volume went from 52 filings in 2024 to 5 in 2025. In the last twelve months: 24 filings, 6 sales and no purchase. For 17 purchases a 90-day result is stored: a median of 1.9%, with 100% of results positive, recorded past results and not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
